of the tendon from the eyelid tissue.³ This produces a rounding of the lateral angle and acquired blepharophimosis. The dark discoloration over the lateral canthus can precede the tendon dehiscence.

Blepharochalasis is an uncommon condition and Brazin commented that its occurrence unilaterally was extremely rare.⁴ This view is supported by Langley *et al.*⁵ Collin, however, reported a series of 30 cases where 14 cases were unilateral.⁶ This may reflect the referral pattern of diagnostically difficult cases to one centre.

No previously reported cases have described a localised example of blepharochalasis. Our patient had normal skin and periorbital in the medial aspect of the left upper and lower eyelids which did not require surgery. The main differential diagnosis in this case was of a vascular lesion but this was excluded at surgery together with other infiltrative lesions. The clinical

features did not suggest lacrimal gland involvement.

The diagnosis of blepharochalasis can be difficult if the condition is localised or unilateral. Our case shows how characteristic changes in the skin and periorbital, together with a classic history and the exclusion of other causes of lid swelling, all help in the diagnosis of an atypical case of blepharochalasis.

- 1 Alvis BY. Blepharochalasis. Report of a case. *Am J Ophthalmol* 1935; 18: 238-45.
- 2 Fuchs E. Ueber Blepharochalasis (Erchlaffung der Lidhaut). *Wien Klin Wochenschr* 1896; 9: 109-10.
- 3 Custer PL, Tenzel RR, Kowalczyk AP. Blepharochalasis syndrome. *Am J Ophthalmol* 1985; 99: 424-8.
- 4 Brazin SA, Stern LJ, Taylor-Johnson W. Unilateral blepharochalasis. *Arch Dermatol* 1979; 115: 479-81.
- 5 Langley KE, Anderson RL, Patrinely JR, Thiese SM. Unilateral blepharochalasis. *Ophthalmic Surg* 1987; 18: 594-8.
- 6 Collin JRO. Blepharochalasis. A review of 30 cases. *Ophthalm Plast Reconstr Surg* 1991; 7: 153-7.

British Journal of Ophthalmology 1994; 78: 882

Superior oblique myokymia – a topical solution?

Kim Bibby, James S Deane, David Farnworth, John Cappin

Superior oblique myokymia (SOM) is a rare ocular motility disorder characterised by a monocular high frequency, low amplitude cyclo-torsional tremor. It occurs intermittently, giving rise to sometimes obtrusive symptoms of oscillopsia and diplopia.

Case report

A 50-year-old woman presented to the eye casualty department, Leicester Royal Infirmary with a 13-month history. She described oscillopsia and a feeling of tremor in her left eye. The symptoms occurred periodically and were particularly troublesome when she was reading. On examination, visual acuity was 6/6 unaided. Anterior segments, pupil reflexes, and funduscopy were unremarkable. Lid position was normal and she had a full range of ocular movements. Slit-lamp biomicroscopy disclosed a cyclotorsional tremor of fine amplitude with a vertical element. This was intermittent but could be induced by her looking down and to the right.

We prescribed betaxolol drops twice daily to the left eye for 1 month, and reviewed the woman after 2 months. In the 4 weeks she had been using the drops she had been asymptomatic, but her problem returned within 1 week of stopping treatment. On examination left SOM was apparent. She recommenced topical betaxolol and when reviewed at 3 and 6 months was totally asymptomatic. No SOM was observed on six separate occasions during these two outpatient appointments.

Comment

Superior oblique myokymia was described as a distinct entity by Hoyt and Keane as a benign, periodic uniocular vertical and rotary micro-tremor.¹ It is rarely associated with serious underlying pathology, but can be disturbing symptomatically. Susac and Smith report successful elimination of symptoms with the use of carbamazepine, and go on to advocate superior oblique myotomy for intractable cases, or patients who cannot tolerate the drug.² Propranolol is cited as a pharmacological alternative by Tyler and Ruiz.³

Leigh *et al* describe success with the use of a topical β blocker in one patient.⁴

Betaxolol has weak membrane stabilising effects compared with other β blockers and is unlikely to work topically. However, it has a bioavailability of 89% and demonstrates significant reduction in finger tremor when administered parenterally.⁵ We hypothesise that enough betaxolol may be absorbed systemically to eliminate SOM. The drug is cardioselective and has fewer of the side effects associated with propranolol or carbamazepine. It may be of use as a first line treatment in those patients whose symptoms are intolerable.

- 1 Hoyt WF, Keane JR. Superior oblique myokymia. *Arch Ophthalmol* 1970; 84: 461-7.
- 2 Susac JO, Smith JL. Superior oblique myokymia. *Arch Neurol* 1973; 29: 432-4.
- 3 Tyler TD, Ruiz RS. Propranolol in the treatment of superior oblique myokymia. *Arch Ophthalmol* 1990; 108: 175-6.
- 4 Leigh JR, Tomsak RL, Seidman MS, Dell'Osso LF. Superior oblique myokymia. Quantitative analysis of the eye movements in three patients. *Arch Ophthalmol* 1991; 109: 1710-3.
- 5 Irvine NA, Lipworth BJ, McDevitt DG. A dose-ranging study to evaluate the beta-adrenoceptor selectivity of single doses of betaxolol. *Br J Pharmacol* 1990; 30: 119-26.

Leicester Royal Infirmary
K Bibby
JS Deane
D Farnworth
J Cappin

Correspondence to:
Kim Bibby, Department of
Ophthalmology, Leicester
Royal Infirmary, Leics LE1.

Accepted for publication
14 June 1994